New cancer drugs list

Here is a list of new cancer drugs that have been approved by regulatory agencies such as the US FDA, EMA, and PMDA in recent years:

2019

  1. Brexucabtagene autoleucel (Tecartus): A CAR-T cell therapy for relapsed or refractory B-cell lymphoma.
  2. Pemigatinib (Pemazyre): An oral FGFR inhibitor for cholangiocarcinoma.
  3. Zanubrutinib (Brukinsa): An oral BTK inhibitor for mantle cell lymphoma.
  4. Fam-trastuzumab deruxtecan-nxki (Enhertu): A HER2-targeted antibody-drug conjugate for HER2-positive breast cancer.
  5. Lurbinectedin (Zepzelca): An oral DNA-binding agent for small cell lung cancer.

2020

  1. Tisotumab vedotin (Tivdak): An anti-TFPI antibody-drug conjugate for recurrent or metastatic cervical cancer.
  2. Pembrolizumab (Keytruda): A PD-1 inhibitor for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors.
  3. Rucaparib (Rubraca): An oral PARP inhibitor for BRCA-mutated, HER2-negative advanced ovarian cancer.
  4. Enfortumab vedotin (Padcev): An anti-Nectin-4 antibody-drug conjugate for locally advanced or metastatic urothelial cancer.
  5. Capmatinib (Tabrecta): An oral MET inhibitor for non-small cell lung cancer.

2021

  1. Tazemetostat (Tazverik): An oral EZH2 inhibitor for follicular lymphoma.
  2. Ripretinib (Qinlock): An oral c-KIT inhibitor for gastrointestinal stromal tumor (GIST).
  3. Fexinidazole (Fexinidazole): An oral diamidine for trypanosomiasis (sleeping sickness).
  4. Pembrolizumab (Keytruda): A PD-1 inhibitor for advanced melanoma.
  5. Lenvatinib (Lenvima): An oral VEGFR inhibitor for thyroid cancer.

2022

  1. Talquetamab (Talquetamab): An anti-CD19 antibody-drug conjugate for relapsed or refractory multiple myeloma.
  2. Pemigatinib (Pemazyre): An oral FGFR inhibitor for cholangiocarcinoma.
  3. Fam-trastuzumab deruxtecan-nxki (Enhertu): A HER2-targeted antibody-drug conjugate for HER2-positive breast cancer.
  4. Rucaparib (Rubraca): An oral PARP inhibitor for BRCA-mutated, HER2-negative advanced ovarian cancer.
  5. Capmatinib (Tabrecta): An oral MET inhibitor for non-small cell lung cancer.

Please note that this is not an exhaustive list, and new cancer drugs are being approved regularly. Additionally, the list only includes drugs that have been approved by regulatory agencies and may not include experimental or investigational treatments.